All In Biotech

Drug Trial Radar · NCT02375880

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder

Last checked: Nov 19, 2026Latest source record: Aug 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

51

Actual

Start

Jun 2015

Primary completion

Jul 2018

Study completion Jul 2018

Sponsor

Lead sponsor
Leap Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 3, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

DKN-01 is a humanized monoclonal antibody (Mab) with neutralizing activity against Dkk-1 and is being developed as an anti-neoplastic agent. This study is designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of DKN-01 in combination with gemcitabine and cisplatin in patients with carcinoma primary to the intra- or exta-hepatic biliary system or gallbladder.

Conditions

  • Carcinoma of Intrahepatic and Extra-hepatic Biliary System
  • Carcinoma of Gallbladder
  • Bile Duct Cancer
  • Cholangiocarcinoma

Interventions

  • DKN-01Drug

    Administration by intravenous (IV) infusion.

  • gemcitabineDrug

    Administered by IV infusion.

  • cisplatinDrug

    Administered by IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose and dose-limiting toxicities as determined in Part A.Time frame: End of Cycle 1 (Day 21)
  2. Composite Safety parameters as assessed by new or changing physical examinations, vital signs, electrocardiograms (ECGs), clinical laboratories, concomitant medication reviews, and assessment of adverse events.Time frame: Parts A and B: at a minimum Days 1, 8, 15 of each treatment cycle.

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of Southern California

    Los Angeles, California

  • Yale University

    New Haven, Connecticut

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Columbia University Medical Center

    New York, New York

  • University Hospitals, Case Medical Center

    Cleveland, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.